Moreover, in vitro and animal experiments showed that A1R overexpression promoted cancer cell proliferation via the phosphoinositide-3-kinase (PI3K)/AKT pathway and that treatment with the specific A1R antagonist DPCPX suppressed tumour progression in hepatocellular carcinoma. This evidence concerns the gene AKT1 and neoplasm.